The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer

被引:17
作者
Gidwani, Bina [1 ]
Vyas, Amber [1 ]
机构
[1] Pt Ravi Shankar Shukla Univ, Univ Inst Pharm, Raipur, CG, India
关键词
chemotherapy; delivery system; nanotechnology; ovarian cancer; SOLID LIPID NANOPARTICLES; PACLITAXEL; FORMULATION; PHARMACOKINETICS; CHEMOTHERAPY; DOXORUBICIN; MANAGEMENT; CARCINOMA; NIOSOMES; TOXICITY;
D O I
10.3109/21691401.2013.853179
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ovarian cancer is one of the leading causes for death of women. Every year the percentage of mortality rate is increasing day by day. Various chemotherapeutic agents are used to increase the survival rate of patients with ovarian cancer, but the available conventional dosage forms/marketed preparations are associated with several limitations. The use of nanotechnology in drug delivery contributes to their small size (10-100 nm), which improves the circulation and enables superior accumulation of therapeutic drugs at the tumor sites. In future, the use of nanotechnology will enable passive targeting and further improvements can be made using targeting moieties.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 59 条
  • [51] Role of pegylated liposomal doxorubicin in ovarian cancer
    Thigpen, JT
    Aghajanian, CA
    Alberts, DS
    Campos, SM
    Gordon, AN
    Markman, M
    McMeekin, DS
    Monk, BJ
    Rose, PG
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 10 - 18
  • [52] The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models
    Uchegbu, IF
    Double, JA
    Kelland, LR
    Turton, JA
    Florence, AT
    [J]. JOURNAL OF DRUG TARGETING, 1996, 3 (05) : 399 - 409
  • [53] Vyas A, 2011, ORIENT J CHEM, V27, P359
  • [54] Vyas A, 2012, J INCL PHEN MACROCYC, V66, P251
  • [55] Cyclodextrin based novel drug delivery systems
    Vyas, Amber
    Saraf, Shailendra
    Saraf, Swarnlata
    [J]. JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2008, 62 (1-2) : 23 - 42
  • [56] Scope of nanotechnology in ovarian cancer therapeutics
    Yallapu, Murali M.
    Jaggi, Meena
    Chauhan, Subhash C.
    [J]. JOURNAL OF OVARIAN RESEARCH, 2010, 3
  • [57] Nanoparticles in medicine: Therapeutic applications and developments
    Zhang, L.
    Gu, F. X.
    Chan, J. M.
    Wang, A. Z.
    Langer, R. S.
    Farokhzad, O. C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 761 - 769
  • [58] Pharmacokinetics in Rats and Efficacy in Murine Ovarian Cancer Model for Solid Lipid Nanoparticles Loading Docetaxel
    Zhang, Pengcheng
    Chen, Lingli
    Zhang, Zhiwen
    Lin, Liping
    Li, Yaping
    [J]. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (11) : 7541 - 7544
  • [59] The cyclin-dependent kinase inhibitor p21cip1/waf1 enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells
    Ziller, C
    Lincet, H
    Muller, CD
    Staedel, C
    Behr, JP
    Poulain, L
    [J]. CANCER LETTERS, 2004, 212 (01) : 43 - 52